GT Biopharma Inc is a biotechnology company focused on developing innovative immuno-oncology therapies to treat various forms of cancer. The company specializes in harnessing the power of the immune system to identify and destroy cancer cells through its proprietary platforms, which include novel antibody constructs and immune cell engineering. By advancing its therapeutic candidates through clinical trials, GT Biopharma aims to improve treatment outcomes for patients suffering from solid tumors and hematological malignancies. Through strategic partnerships and cutting-edge research, the company is dedicated to addressing unmet medical needs in the oncology space. Read More
NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face limited treatment options and uncertain outcomes. Scientists have increasingly turned to the body's own defenses, developing therapies that empower natural killer (NK) cells to seek and destroy malignant cells. These next-generation approaches combine precision, potency, and the potential for fewer side effects than conventional treatments.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
GT Biopharma's Phase 1 trial of GTB-3650 progresses with early safety signals, immune activation, and plans to advance to higher dose cohorts into 2026.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
